Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)

This is a first in children prospective study of allogeneic hematopoietic cell transplant using a centrally manufactured engineered donor graft (Orca-Q). The study will assess safety and efficacy of Orca-Q in pediatric patients with hematologic malignancies.

Trial Details

NCT ID
NCT05322850
Phase
PHASE1 / PHASE2
Sponsor
University of Florida
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Orca-Q
Locations (sample)
  • Gainesville, Florida, United States|29.65163,-82.32483
  • Miami, Florida, United States|25.77427,-80.19366
  • Miami, Florida, United States|25.77427,-80.19366
  • St. Petersburg, Florida, United States|27.77086,-82.67927

Key Eligibility Criteria

  • Age \< 22 years of age at the time of diagnosis of malignancy
  • Eligible for treatment at a pediatric HCT center
  • Patients with the following histopathologically-confirmed diseases are eligible:
  • Acute myeloid, lymphoid, mixed phenotype or undifferentiated leukemia in complete remission (CR) or CR with incomplete hematologic recovery (CRi) a…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →